Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms

详细信息    查看全文

• 作者：M. Untch (1)
  Prof. Dr. C. Thomssen (2)
  
  1. Klinik f眉r Gyn盲kologie und Geburtshilfe ; HELIOS Klinikum Berlin-Buch ; Berlin ; Deutschland
  2. Klinik und Poliklinik f眉r Gyn盲kologie ; Martin-Luther-Universit盲t Halle-Wittenberg ; Ernst-Grube-Stra脽e 40 ; 06120 ; Halle an der Saale ; Deutschland
  
• 关键词：Adjuvant ; Neoadjuvant ; Chemotherapie ; Pathologische Komplettremission ; Molekulare Typen ; Adjuvant ; Neoadjuvant ; Chemotherapy ; Pathological complete response ; Molecular subtypes
• 刊名：Der Onkologe
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：21
• 期：3
• 页码：231-238
• 全文大小：602 KB
• 参考文献：1. Early, (2012) Lancet 379: pp. 432 CrossRef
  2. AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2014. http://www.ago-online.de, download 8.12.2014
  3. NCCN Guidelines. (http://www.nccn.org; Version 2.2014; download 15.3. 2014)
  4. Schlitt, (2014) Dtsch Arztebl Int 111: pp. 161
  5. Jones, (2009) J Clin Oncol 27: pp. 1177 CrossRef
  6. Slamon, (2011) N Engl J Med 365: pp. 1273 CrossRef
  7. Citron, (2003) J Clin Oncol 21: pp. 1431 CrossRef
  8. Cognetti F, Bruzzi P, De Placido S et al (2013) Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. Vortrag San Antonio Breast Cancer Symposium S5鈥?6
  9. Moebus, (2010) J Clin Oncol 28: pp. 2874 CrossRef
  10. Budd GT, Barlow WE, Moore HCF et al (2013) S0221: comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol (suppl; abstr CRA1008)
  11. Sikov WM, Berry DA, Perou CM et al (2014) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. pii: JCO.2014.57.0572
  12. Brito, (2001) J Clin Oncol 19: pp. 628
  13. Fisher, (1997) J Clin Oncol 15: pp. 2483
  14. Kaufmann, (2006) J Clin Oncol 24: pp. 1940 CrossRef
  15. Minckwitz, (2011) Breast Cancer Res Treat 125: pp. 145 CrossRef
  16. Mamounas, (2012) J Clin Oncol 30: pp. 3960 CrossRef
  17. Nes, (2009) Breast Cancer Res Treat 115: pp. 101 CrossRef
  18. U. S. Food and Drug Administration. Accelerated approval pertuzumab. Sep 30, 2013. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm370449.htm. Zugegriffen: 13. Dez. 2014
  19. Minckwitz, (2011) Cancer Res 24: pp. S3
  20. Loibl, (2011) Cancer Res 24: pp. S5
  21. Minckwitz, (2011) Breast Cancer Res Treat 125: pp. 145 CrossRef
  22. Gianni, (2010) Lancet 375: pp. 377 CrossRef
  23. Untch, (2011) J Clin Oncol 29: pp. 3351 CrossRef
  24. Cortazar, (2014) Lancet 38: pp. 164 CrossRef
  25. Petrelli, (2012) Med Oncol 29: pp. 503 CrossRef
  26. Gianni, (2012) Lancet Oncol 13: pp. 25 CrossRef
  27. Buzdar, (2013) Lancet Oncol 14: pp. 1317 CrossRef
  28. Tolaney SM, Barry WT, Dang CT et al (2013) A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Vortrag San Antonio Breast Cancer Symposium S1鈥?4
  29. Slamon, (2011) N Engl J Med 365: pp. 1273 CrossRef
  30. Jones, (2013) Lancet Oncol 14: pp. 1121 CrossRef
  31. Minckwitz, (2014) Lancet Oncol 15: pp. 747 CrossRef
  32. Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat
  33. Cameron, (2013) Lancet Oncol 14: pp. 933 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0415

文摘

Background Adjuvant treatment modalities have significantly improved the prognosis of early breast cancer. Neoadjuvant systemic therapy is recommended in patients with locally advanced, inoperable or inflammatory breast cancer and is increasingly being used in patients with high-risk operable primary breast cancer. Objective Evaluation of adjuvant and neoadjuvant treatment regimens for different patient subgroups as well as the results of current clinical studies. Material and methods Interpretation of current evidence on adjuvant and neoadjuvant therapy, review of treatment recommendations and current study concepts. Results Adjuvant and neoadjuvant chemotherapy with anthracyclines, cyclophosphamide and taxanes are equally effective regarding survival. There is a correlation between the achievement of pathological complete response (pCR) and prolonged survival, especially in patients with hormone receptor-negative (after chemotherapy) and HER2-positive tumors (after chemotherapy and trastuzumab). Conclusion For patients without pCR, the prognosis is less favorable and new postoperative therapies are necessary, mainly in prospective randomized trials. Dose-dense (neo)adjuvant chemotherapies are increasingly considered as preferred regimens. For patients without pCR, the prognosis is less favorable and new postoperative therapies are necessary, mainly in prospective randomized trials.